AMRN
Drug Manufacturers - General · Healthcare
Board Member
2021-04-29–present
Board Member
Amarin Corp Plcuk (AMRN)Equibles does not estimate personal net worth.
Get an email with a short summary when Amarin Corp Plcuk publishes a filing, an earnings call transcript or a press release.
Get AMRN alertsKarim Mikhail is recorded as Board Member at Amarin Corp Plcuk (AMRN) since August 1, 2021. Amarin Corp Plcuk reported in an 8-K filed March 31, 2023 that Karim Mikhail resigned as President and Chief Executive Officer, effective March 27, 2023. The proxy statement of Amarin Corp Plcuk reports total compensation of $4,880,592 for Karim Mikhail in fiscal 2023, including a base salary of $221,585. Disclosed compensation is on record for 3 fiscal years. Karim Mikhail has spoken on 8 earnings calls across 1 company, most recently for Amarin Corp Plcuk on January 10, 2023. Amarin Corp Plcuk is classified in the Drug Manufacturers - General industry within the Healthcare sector. Other leadership on record at Amarin Corp Plcuk includes Aaron D. Berg (CEO), Patrick Holt (CEO and Board Member), Odysseas D. Kostas (Chairman) and 7 others.
“On March 27, 2023, Karim Mikhail notified Amarin Corporation plc (the "Company") of his decision to resign as President and Chief Executive Officer of the Company, effective immediately.”
“While 2022 was a challenging year for Amarin, it was also a year filled with significant accomplishments that we believe have created the foundation for our future and gives us confidence that 2023 will be a year of tremendous evolution for the company.”
“We began this year embarking on a bold strategy to grow and expand globally. We focused on our three-dimensional growth strategy: breadth, representing geographic expansion; heights, representing diversification; and depth, representing core operational evolution.”
“As we enter the second half of this pivotal year for Amarin, we continue to focus on our three-dimensional growth strategy: breadth, representing geographic expansion; height, representing diversification; and depth, representing core operational evolution.”
“We entered 2022 noting that this is a year of execution for Amarin and to date we have accomplished important milestones and are on track to achieve the goals we have set for the year.”
“2021 was an evolutionary year for Amarin, marked by our transformation to a truly global commercial company. Last August, we outlined our vision for our three-dimensional growth strategy, breadth or geographic expansion, height representing diversification and depth or core operational evolution.”
2021-08-01–present
SEC 8-K
2021-04-29–present
Start not stated–2023-03-27
AMRN
Drug Manufacturers - General · Healthcare
Board Member
2021-04-29–present
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2023 | Amarin Corp Plcuk (AMRN) | Former President and Chief Executive Officer | $221,585 | $4,880,592 |
| 2022 | Amarin Corp Plcuk (AMRN) | Former President and Chief Executive Officer | $799,637 | $8,393,551 |
| 2021 | Amarin Corp Plcuk (AMRN) | Former President and Chief Executive Officer | $672,747 | $5,834,553 |